Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPular GUILTY PILOT genotype-guided clopidogrel monotherapy
NL-OMON60251Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clopidogrel in acute coronary syndrome (ACS) and coronary arteriosclerosis, sponsored by St. Antonius Ziekenhuis. Primary endpoints: Primary ischemic endpoint at 6 months and Primary bleeding endpoint at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON60251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60251.